Cargando…

Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis

BACKGROUND: The mortality from all malignant and nonmalignant asbestos-related diseases remains unknown. The authors assessed the incidence and risk factors for all asbestos-related deaths. METHODS: The sample included 544 patients from an asbestos-exposed community in the area of Barcelona (Spain),...

Descripción completa

Detalles Bibliográficos
Autores principales: Abós-Herràndiz, Rafael, Rodriguez-Blanco, Teresa, Garcia-Allas, Isabel, Rosell-Murphy, Isabel-Magdalena, Albertí-Casas, Constança, Tarrés, Josep, Krier-Günther, Illona, Martinez-Artés, Xavier, Orriols, Ramon, Grimau-Malet, Isidre, Canela-Soler, Jaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478817/
https://www.ncbi.nlm.nih.gov/pubmed/28680295
http://dx.doi.org/10.1155/2017/9015914
Descripción
Sumario:BACKGROUND: The mortality from all malignant and nonmalignant asbestos-related diseases remains unknown. The authors assessed the incidence and risk factors for all asbestos-related deaths. METHODS: The sample included 544 patients from an asbestos-exposed community in the area of Barcelona (Spain), between Jan 1, 1970, and Dec 31, 2006. Competing risk regression through a subdistribution hazard analysis was used to estimate risk factors for the outcomes. RESULTS: Asbestos-related deaths were observed in 167 (30.7%) patients and 57.5% of these deaths were caused by some type of mesothelioma. The incidence rate after diagnosis was 3,600 per 100,000 person-years. In 7.5% of patients death was non-asbestos-related, while pleural and peritoneal mesothelioma were identified in 87 (16.0%) and 18 (3.3%) patients, respectively. CONCLUSIONS: Age, sex, household exposure, cumulative nonmalignant asbestos-related disease, and single malignant pathology were identified as risk factors for asbestos-related death. These findings suggest the need to develop a preventive approach to the community and to improve the clinical follow-up process of these patients.